Koru Pharma is pleased to announce a strategic partnership with LYFE Capital, a global healthcare investment firm, marking a significant milestone in the company’s continued international growth journey.

This collaboration brings together Koru Pharma’s scientific expertise in regenerative aesthetics with LYFE Capital’s deep sector knowledge and global investment capabilities. With a strong track record in scaling healthcare and medical aesthetics businesses, LYFE Capital provides strategic insight and access to an extensive international network.

The partnership reflects Koru Pharma’s long-term vision to strengthen its global presence and enhance its ability to deliver innovation at scale. By aligning with a partner that understands the evolving dynamics of the aesthetics industry, Koru Pharma is well positioned to accelerate product development, expand into new markets, and reinforce its role as a trusted partner to clinicians and distributors worldwide.

LYFE Capital manages over USD 2 billion in assets and operates across major global hubs, including Seoul, the United States, Singapore, Japan, and China. Its focused investment approach in healthcare and aesthetic medicine makes it a natural partner at this stage of Koru Pharma’s growth.

As demand for regenerative and performance-driven aesthetic solutions continues to rise, this partnership further strengthens Koru Pharma’s commitment to advancing science-led innovation and supporting the global medical community.

Koru Pharma looks forward to this next phase of growth, with a continued focus on delivering long-term value to its partners and contributing to the future of aesthetic medicine.